Literature DB >> 6479529

Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels.

H P Festen, J C Thijs, C B Lamers, J M Jansen, G Pals, R R Frants, J Défize, S G Meuwissen.   

Abstract

Fasting and meal-stimulated serum gastrin and serum pepsinogen I levels were determined in 8 healthy volunteers before, during, and after administration of 30 mg of omeprazole daily for 14 days. Fasting levels and the integrated increment of serum gastrin were significantly increased after 7 and 14 days of treatment with omeprazole, but not after a single dose. Fasting levels measured 2, 4, 7, 14, and 21 days after stopping treatment with omeprazole and the integrated increment of serum gastrin determined 7 and 14 days after discontinuation of omeprazole were not significantly different from pretreatment levels. Fasting serum pepsinogen I levels increased progressively during omeprazole treatment. This increase was significant after 7 and 14 days of treatment and 2 and 4 days after discontinuing omeprazole. These levels were not significantly different from pretreatment levels 7, 14, and 21 days after omeprazole treatment. Serum pepsinogen I did not significantly change after the test meal. It is concluded that fasting and meal-stimulated serum gastrin levels and fasting serum pepsinogen I levels increase significantly during treatment with 30 mg of omeprazole daily for 14 days, but after stopping treatment there is a rapid return to pretreatment levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6479529

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Influence of acid-pepsin secretion on gastric emptying of solids in humans: studies with cimetidine.

Authors:  D D Kerrigan; Y F Mangnall; N W Read; A G Johnson
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

2.  Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens.

Authors:  L C Baak; J B Jansen; I Biemond; C B Lamers
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Effect of short-term omeprazole administration on serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion.

Authors:  I Biemond; L F Crobach; J B Jansen; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease.

Authors:  M Coupe; H Rees; C J Springer; A E Bishop; J A Morris; J M Polak; J Calam
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

5.  Effect of single and repeated doses of oral omeprazole on gastric acid and pepsin secretion and fasting serum gastrin and serum pepsinogen I levels.

Authors:  H P Festen; H A Tuynman; J Défize; G Pals; R R Frants; J P Straub; S G Meuwissen
Journal:  Dig Dis Sci       Date:  1986-06       Impact factor: 3.199

Review 6.  Achlorhydria: hypergastrinaemia: carcinoids--a flawed hypothesis?

Authors:  J Penston; K G Wormsley
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

7.  Effects of single daily doses of a pyridil-2-tetrahydrothiophene derivative (40749 RP) on 24 hour H+ activity, nocturnal acid output, gastrin and pepsinogen I profiles in duodenal ulcer patients.

Authors:  P J Malè; M Griessen; M G Cunningham; A M Frydman; N A Garoflid-Oprescu; R De Peyer; E Loizeau
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

8.  Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia.

Authors:  M Renga; G Brandi; G M Paganelli; C Calabrese; S Papa; A Tosti; P Tomassetti; M Miglioli; G Biasco
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

9.  A long lasting gastrin response to apomorphine revealed by inhibitors of gastric acid secretion.

Authors:  M Goiny; K Brodin; C E Elwin; K Uvnäs-Moberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

Review 10.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.